Biocon Limited

Biocon India Limited

Anand Khedkar

Shrikumar Suryanarayan

Ramakrishnan Melarkode

Harish Iyer

Nitin Patil

Nitesh Dave

Ramavana Gururaja

Rakesh Bhaiyyaram Mendhe

Anindya Sircar

Sanjay Tiwari

Laxmi Adhikary

Partha Hazra

Surekha K Prabhu

Madhav Kulkarni

Pampapathy Subramaniyam

Gautam Krishnan

Madenahally Channabasappa Shivakumar

Sambasivam Ganesh

Madhavan Sridharan

Anuj Goel

Mukesh Babuappa Patale

Prijyajit Sengupta

Shreehas Pradeep Tambe

Poornaprajna Acharya

Mayank Kumar Garg

Harish Venkatraman Pai

Goldy Sachdev

Nita Roy

Manjunath Hadavanahalli Shivarudraiah

Nilanjan Sengupta

Madhavan Buddha

Konayakanahalli Nanjunda Swamy Anand

Melarkode Ramkrishna

Madhay Kulkarni

Ganesh Samvasivam

Govindasamy Manikam

H S Manjunath

Shanmugam Thandava Murthy

Ranjith Ramakrishna

Sudheer Chivukula

Sundaresh Shankar

Devesh Radhakrishnan

Ramesh Subramani

Sharath Kumar Mallapura Rangappa

Sharath Kumar Rangappa

Madenahalli Channabasappa Shivakumar

Sebastian Alastair Mcdonald

Ranitendranath Tagore

M C Shivakumar

Mayank Garg

The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.

Orally administrable solid pharmaceutical composition and a process thereof

The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC&#x2014;CH&#x2014;CH&#x2014;(OCHCH)&#x2014;OCH.

Process for the preparation of insulin conjugate IN-105

The present invention discloses a new strain ofsp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of macrolides.

[object Object]

The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.

Preparation of insulin conjugates

The present invention discloses a new strain ofsp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of microlides.

The invention relates to a process for the recovery of a macrolide in substantial pure form including:

Process for the purification of macrolides

The present invention provides an improved method for the manufacture of Cyclosporin A is disclosed. Cyclosporin A is produced by solid state fermentation ofin a bioreactor under optimal fermentation parameters. The product is extracted and further purified by treating with alum and subsequent chromatographic procedures to get pharmaceutical acceptable purity.

Manufacture and purification of cyclosporin A

The present invention provides an improved method for the manufacture of Mycophenolic acid by solid substrate fermentation of, in a contained bioreactor under optimal fermentation parameters with its subsequent purification steps.

Manufacture and purification of mycophenolic acid

Methods for the manufacture of Mycophenolate are disclosed. Mycophenblate mofetil is biochemically synthesized using Mycophenolic Acid and 2-morpholino ethanol with the help of an enzyme. Mycophenolate mofetil is also chemically synthesized non-catalytically by refluxing mycophenolic acid with 2-morpholino ethanol in the absence of a third solvent or a catalyst.

Methods of producing esters of mycophenolate

Growing community of inventors

Karnataka, India

Anand Khedkar